Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial

Background and aim Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao...

Full description

Saved in:
Bibliographic Details
Published inHepatology international Vol. 14; no. 6; pp. 985 - 996
Main Authors Li, Xiaoke, Zhou, Daqiao, Chi, Xiaoling, Li, Qin, Wang, Li, Lu, Bingjiu, Mao, Dewen, Wu, Qikai, Wang, Xianbo, Zhang, Mingxiang, Xue, Jingdong, Li, Yong, Lu, Wei, Guo, Jianchun, Jiang, Feng, Zhang, Xinwei, Li, Zhiguo, Yang, Xianzhao, Guo, Hui, Gan, Danan, He, Liyun, Luo, Lin, Zhang, Ludan, Du, Hongbo, Ye, Yong’an
Format Journal Article
LanguageEnglish
Published New Delhi Springer India 01.12.2020
Springer Nature B.V
Subjects
Adverse events
Antigens
Antiviral Agents - therapeutic use
Antiviral drugs
Clinical trials
Colorectal Surgery
Deoxyribonucleic acid
DNA
DNA, Viral
Drug Combinations
Drugs, Chinese Herbal - therapeutic use
Enzymes
Granular materials
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis
Hepatitis B
Hepatitis B e antigen
Hepatitis B e Antigens
Hepatitis B surface antigen
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Hepatology
Herbal medicine
Humans
Liver
Medicine
Medicine & Public Health
Nucleoside analogs
Original Article
Placebos
Statistical analysis
Surgery
Therapy
Traditional Chinese medicine
Treatment Outcome
Traditional Chinese medicine
Tiao-gan-yi-pi granule
Chronic hepatitis B
Tiao-gan-jian-pi-jie-du granule
Online AccessGet full text

Cover

Abstract Background and aim Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao-Gan-Jian-Pi-Jie-Du granule (TGJPJD) increase the rate of hepatitis B e antigen (HBeAg) loss in Chinese patients. Methods 596 eligible participants were randomly assigned, in a 1:1 ratio, to two study groups in this 108-week trial: The experiment group was assigned ETV plus the TCM formula. The control group was assigned ETV plus a TCM placebo. We compared the rate of HBeAg loss by the end of week 108 between the two arms as the primary outcome. Secondary outcomes included hepatitis B surface antigen (HBsAg) level, proportion of undetectable HBV-DNA, and liver enzymes (ALT, AST, GGT) at week 108. Results The combination therapy achieved superior HBeAg loss at 108 weeks, without additional adverse events. The rate of HBeAg loss at week 108 was 37.54% (95% CI 31.9–43.2%) in the experiment group and 27.21% (95% CI 22.0–32.4%) in the control group. There was a statistically significant difference between the two arms of 10.33% (95% CI 8.4–12.3%, p  = 0.008). The DNA loss rate, serum HBsAg level, and liver enzymes were similar between the groups by the end of 108th week. Conclusion Combining the Chinese herbal formula with ETV therapy demonstrated superior HBeAg clearance compared with ETV monotherapy. This finding indicates that this combined therapy could produce an improved therapeutic effect and safety profile. Clinical trial number ChiCTR-TRC-12002784 (Chinese Clinical Trial Registry).
AbstractList Background and aim Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao-Gan-Jian-Pi-Jie-Du granule (TGJPJD) increase the rate of hepatitis B e antigen (HBeAg) loss in Chinese patients. Methods 596 eligible participants were randomly assigned, in a 1:1 ratio, to two study groups in this 108-week trial: The experiment group was assigned ETV plus the TCM formula. The control group was assigned ETV plus a TCM placebo. We compared the rate of HBeAg loss by the end of week 108 between the two arms as the primary outcome. Secondary outcomes included hepatitis B surface antigen (HBsAg) level, proportion of undetectable HBV-DNA, and liver enzymes (ALT, AST, GGT) at week 108. Results The combination therapy achieved superior HBeAg loss at 108 weeks, without additional adverse events. The rate of HBeAg loss at week 108 was 37.54% (95% CI 31.9–43.2%) in the experiment group and 27.21% (95% CI 22.0–32.4%) in the control group. There was a statistically significant difference between the two arms of 10.33% (95% CI 8.4–12.3%, p  = 0.008). The DNA loss rate, serum HBsAg level, and liver enzymes were similar between the groups by the end of 108th week. Conclusion Combining the Chinese herbal formula with ETV therapy demonstrated superior HBeAg clearance compared with ETV monotherapy. This finding indicates that this combined therapy could produce an improved therapeutic effect and safety profile. Clinical trial number ChiCTR-TRC-12002784 (Chinese Clinical Trial Registry).
Background and aimTraditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao-Gan-Jian-Pi-Jie-Du granule (TGJPJD) increase the rate of hepatitis B e antigen (HBeAg) loss in Chinese patients.Methods596 eligible participants were randomly assigned, in a 1:1 ratio, to two study groups in this 108-week trial: The experiment group was assigned ETV plus the TCM formula. The control group was assigned ETV plus a TCM placebo. We compared the rate of HBeAg loss by the end of week 108 between the two arms as the primary outcome. Secondary outcomes included hepatitis B surface antigen (HBsAg) level, proportion of undetectable HBV-DNA, and liver enzymes (ALT, AST, GGT) at week 108.ResultsThe combination therapy achieved superior HBeAg loss at 108 weeks, without additional adverse events. The rate of HBeAg loss at week 108 was 37.54% (95% CI 31.9–43.2%) in the experiment group and 27.21% (95% CI 22.0–32.4%) in the control group. There was a statistically significant difference between the two arms of 10.33% (95% CI 8.4–12.3%, p = 0.008). The DNA loss rate, serum HBsAg level, and liver enzymes were similar between the groups by the end of 108th week.ConclusionCombining the Chinese herbal formula with ETV therapy demonstrated superior HBeAg clearance compared with ETV monotherapy. This finding indicates that this combined therapy could produce an improved therapeutic effect and safety profile.Clinical trial numberChiCTR-TRC-12002784 (Chinese Clinical Trial Registry).
Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao-Gan-Jian-Pi-Jie-Du granule (TGJPJD) increase the rate of hepatitis B e antigen (HBeAg) loss in Chinese patients.BACKGROUND AND AIMTraditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao-Gan-Jian-Pi-Jie-Du granule (TGJPJD) increase the rate of hepatitis B e antigen (HBeAg) loss in Chinese patients.596 eligible participants were randomly assigned, in a 1:1 ratio, to two study groups in this 108-week trial: The experiment group was assigned ETV plus the TCM formula. The control group was assigned ETV plus a TCM placebo. We compared the rate of HBeAg loss by the end of week 108 between the two arms as the primary outcome. Secondary outcomes included hepatitis B surface antigen (HBsAg) level, proportion of undetectable HBV-DNA, and liver enzymes (ALT, AST, GGT) at week 108.METHODS596 eligible participants were randomly assigned, in a 1:1 ratio, to two study groups in this 108-week trial: The experiment group was assigned ETV plus the TCM formula. The control group was assigned ETV plus a TCM placebo. We compared the rate of HBeAg loss by the end of week 108 between the two arms as the primary outcome. Secondary outcomes included hepatitis B surface antigen (HBsAg) level, proportion of undetectable HBV-DNA, and liver enzymes (ALT, AST, GGT) at week 108.The combination therapy achieved superior HBeAg loss at 108 weeks, without additional adverse events. The rate of HBeAg loss at week 108 was 37.54% (95% CI 31.9-43.2%) in the experiment group and 27.21% (95% CI 22.0-32.4%) in the control group. There was a statistically significant difference between the two arms of 10.33% (95% CI 8.4-12.3%, p = 0.008). The DNA loss rate, serum HBsAg level, and liver enzymes were similar between the groups by the end of 108th week.RESULTSThe combination therapy achieved superior HBeAg loss at 108 weeks, without additional adverse events. The rate of HBeAg loss at week 108 was 37.54% (95% CI 31.9-43.2%) in the experiment group and 27.21% (95% CI 22.0-32.4%) in the control group. There was a statistically significant difference between the two arms of 10.33% (95% CI 8.4-12.3%, p = 0.008). The DNA loss rate, serum HBsAg level, and liver enzymes were similar between the groups by the end of 108th week.Combining the Chinese herbal formula with ETV therapy demonstrated superior HBeAg clearance compared with ETV monotherapy. This finding indicates that this combined therapy could produce an improved therapeutic effect and safety profile.CONCLUSIONCombining the Chinese herbal formula with ETV therapy demonstrated superior HBeAg clearance compared with ETV monotherapy. This finding indicates that this combined therapy could produce an improved therapeutic effect and safety profile.ChiCTR-TRC-12002784 (Chinese Clinical Trial Registry).CLINICAL TRIAL NUMBERChiCTR-TRC-12002784 (Chinese Clinical Trial Registry).
Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled, randomized, multi-center trial, we evaluated whether entecavir (ETV) plus TCM formulas Tiao-Gan-Yi-Pi granule (TGYP) and Tiao-Gan-Jian-Pi-Jie-Du granule (TGJPJD) increase the rate of hepatitis B e antigen (HBeAg) loss in Chinese patients. 596 eligible participants were randomly assigned, in a 1:1 ratio, to two study groups in this 108-week trial: The experiment group was assigned ETV plus the TCM formula. The control group was assigned ETV plus a TCM placebo. We compared the rate of HBeAg loss by the end of week 108 between the two arms as the primary outcome. Secondary outcomes included hepatitis B surface antigen (HBsAg) level, proportion of undetectable HBV-DNA, and liver enzymes (ALT, AST, GGT) at week 108. The combination therapy achieved superior HBeAg loss at 108 weeks, without additional adverse events. The rate of HBeAg loss at week 108 was 37.54% (95% CI 31.9-43.2%) in the experiment group and 27.21% (95% CI 22.0-32.4%) in the control group. There was a statistically significant difference between the two arms of 10.33% (95% CI 8.4-12.3%, p = 0.008). The DNA loss rate, serum HBsAg level, and liver enzymes were similar between the groups by the end of 108th week. Combining the Chinese herbal formula with ETV therapy demonstrated superior HBeAg clearance compared with ETV monotherapy. This finding indicates that this combined therapy could produce an improved therapeutic effect and safety profile. ChiCTR-TRC-12002784 (Chinese Clinical Trial Registry).
Author Lu, Wei
Wang, Li
Yang, Xianzhao
Zhou, Daqiao
Li, Qin
He, Liyun
Li, Yong
Zhang, Ludan
Li, Zhiguo
Xue, Jingdong
Li, Xiaoke
Gan, Danan
Zhang, Mingxiang
Mao, Dewen
Wu, Qikai
Ye, Yong’an
Wang, Xianbo
Lu, Bingjiu
Jiang, Feng
Du, Hongbo
Zhang, Xinwei
Luo, Lin
Guo, Hui
Chi, Xiaoling
Guo, Jianchun
Author_xml – sequence: 1
  givenname: Xiaoke
  surname: Li
  fullname: Li, Xiaoke
  organization: Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM), Institute of Liver Diseases, BUCM
– sequence: 2
  givenname: Daqiao
  surname: Zhou
  fullname: Zhou, Daqiao
  organization: Department of Hepatology, Shenzhen TCM Hospital
– sequence: 3
  givenname: Xiaoling
  surname: Chi
  fullname: Chi, Xiaoling
  organization: Department of Hepatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine
– sequence: 4
  givenname: Qin
  surname: Li
  fullname: Li, Qin
  organization: Department of Hepatology, Mengchao Hepatobiliary Hospital of Fujian Medical University
– sequence: 5
  givenname: Li
  surname: Wang
  fullname: Wang, Li
  organization: Department of Hepatology, Public Health Clinical Center of Chengdu
– sequence: 6
  givenname: Bingjiu
  surname: Lu
  fullname: Lu, Bingjiu
  organization: Department of Hepatology, Liaoning Hospital of TCM, Huanggu District
– sequence: 7
  givenname: Dewen
  surname: Mao
  fullname: Mao, Dewen
  organization: Department of Hepatology, The First Affiliated Hospital of Guangxi University of Chinese Medicine
– sequence: 8
  givenname: Qikai
  surname: Wu
  fullname: Wu, Qikai
  organization: Department of Hepatology, The Third People’s Hospital of Shenzhen
– sequence: 9
  givenname: Xianbo
  surname: Wang
  fullname: Wang, Xianbo
  organization: Department of Hepatology, Beijing Ditan Hospital
– sequence: 10
  givenname: Mingxiang
  surname: Zhang
  fullname: Zhang, Mingxiang
  organization: Department of Hepatology, The Sixth People’s Hospital of Shenyang
– sequence: 11
  givenname: Jingdong
  surname: Xue
  fullname: Xue, Jingdong
  organization: Department of Hepatology, Shaanxi Hospital of TCM
– sequence: 12
  givenname: Yong
  surname: Li
  fullname: Li, Yong
  organization: Department of Hepatology, The Affiliated Hospital of Shandong University of TCM
– sequence: 13
  givenname: Wei
  surname: Lu
  fullname: Lu, Wei
  organization: Department of Hepatology, Tianjin Second People’s Hospital
– sequence: 14
  givenname: Jianchun
  surname: Guo
  fullname: Guo, Jianchun
  organization: Department of Hepatology, Xixi Hospital of Hangzhou
– sequence: 15
  givenname: Feng
  surname: Jiang
  fullname: Jiang, Feng
  organization: Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM), Institute of Liver Diseases, BUCM
– sequence: 16
  givenname: Xinwei
  surname: Zhang
  fullname: Zhang, Xinwei
  organization: Department of Liver Disease, Fifth Medical Center of Chinese PLA General Hospital
– sequence: 17
  givenname: Zhiguo
  surname: Li
  fullname: Li, Zhiguo
  organization: Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM), Institute of Liver Diseases, BUCM
– sequence: 18
  givenname: Xianzhao
  surname: Yang
  fullname: Yang, Xianzhao
  organization: Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM), Institute of Liver Diseases, BUCM
– sequence: 19
  givenname: Hui
  surname: Guo
  fullname: Guo, Hui
  organization: Department of Hepatology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
– sequence: 20
  givenname: Danan
  surname: Gan
  fullname: Gan, Danan
  organization: Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM), Institute of Liver Diseases, BUCM
– sequence: 21
  givenname: Liyun
  surname: He
  fullname: He, Liyun
  organization: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medicine Sciences
– sequence: 22
  givenname: Lin
  surname: Luo
  fullname: Luo, Lin
  organization: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medicine Sciences
– sequence: 23
  givenname: Ludan
  surname: Zhang
  fullname: Zhang, Ludan
  organization: Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM), Institute of Liver Diseases, BUCM
– sequence: 24
  givenname: Hongbo
  surname: Du
  fullname: Du, Hongbo
  email: duhongbo@bucm.edu.cn
  organization: Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM), Institute of Liver Diseases, BUCM
– sequence: 25
  givenname: Yong’an
  orcidid: 0000-0002-0924-5835
  surname: Ye
  fullname: Ye, Yong’an
  email: yeyongan@vip.163.com
  organization: Department of Gastroenterology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (BUCM), Institute of Liver Diseases, BUCM
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33128206$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtPGzEUha2Kqrz6B7pAltiwYFq_x2EHEZRKSN2UteXx3EmMZuxgO0ikf75OQ6nEAm98ffUd36tzDtFeiAEQ-kLJV0pI-y1TRlrWEEaa-p61zeYDOqAzrhoiBd17rTnfR4c5PxAipaLqE9rnnDLNiDpAv69DAWeffMIuTp0PPizwfOkDZMBLSJ0d8QS9d7WDh5jw7RVcLppVzL74J8BumWLwrqIrW2or4yu8rSCUfIEtTjb0cfIb6M_rgFBSHEfocUnejsfo42DHDJ9f7iN0f3P9a37b3P38_mN-edc43srScC3poDo-9EprQoAqp2TnuJKS6k50uqO6HkGosk4zQQYtZraVA1dABGX8CJ3t_l2l-LiGXMzks4NxtAHiOhsmpBKcKKYrevoGfYjrFOp2lWpbpoTSbaVOXqh1V80xq-Qnm57NP1srwHaASzHnBMMrQonZZmd22ZmanfmbndlUkX4jcr5UK7euWT--L-U7aa5zwgLS_7XfUf0BxkOtSw
CitedBy_id crossref_primary_10_3389_fphy_2021_731972
crossref_primary_10_1038_s41598_021_87812_9
crossref_primary_10_1016_j_ctmp_2024_200183
crossref_primary_10_1016_j_jep_2023_117514
crossref_primary_10_3389_fphar_2022_985084
crossref_primary_10_1016_j_compbiomed_2021_104894
crossref_primary_10_1016_j_jep_2022_115567
crossref_primary_10_3389_fphar_2022_793888
crossref_primary_10_1016_j_jpha_2023_12_017
crossref_primary_10_1016_j_dcmed_2021_09_002
crossref_primary_10_1080_17460794_2024_2388479
Cites_doi 10.14218/JCTH.2016.00019
10.1016/j.taap.2017.03.016
10.1038/ajg.2011.45
10.1007/s11655-020-3250-0
10.1053/j.gastro.2012.07.014
10.1016/j.vaccine.2011.12.116
10.1155/2013/767290
10.1007/s40121-017-0173-y
10.1007/s11655-018-3011-5
10.1016/j.jep.2013.10.033
10.1016/j.jhep.2009.12.036
10.1002/hep.28156
10.1016/j.jhep.2017.05.008
10.1016/j.vaccine.2009.08.048
10.1016/j.jhep.2017.03.021
10.1016/S0168-8278(03)00292-7
10.3851/IMP3280
10.1016/j.eujim.2014.01.005
10.1002/hep.28594
10.1016/j.jhep.2006.08.021
10.1016/j.jpba.2017.02.015
10.1172/JCI118592
10.1016/j.ijbiomac.2017.10.171
10.1046/j.1440-1746.2003.02976.x
10.1111/j.1872-034X.2008.00411.x
10.1111/jvh.12833
10.1016/j.cgh.2013.04.036
10.1016/j.fct.2017.12.020
10.1002/cpdd.317
10.1056/NEJMoa033364
10.3748/wjg.v16.i16.2028
10.1016/j.jhep.2016.05.029
10.1111/j.1365-2893.2010.01271.x
10.1016/S0140-6736(15)61412-X
10.1016/j.jhep.2014.05.044
10.1002/hep.24406
10.1086/599332
10.1007/s12072-015-9675-4
10.5009/gnl16215
10.1053/j.gastro.2007.08.025
ContentType Journal Article
Copyright Asian Pacific Association for the Study of the Liver 2020
Asian Pacific Association for the Study of the Liver 2020.
Copyright_xml – notice: Asian Pacific Association for the Study of the Liver 2020
– notice: Asian Pacific Association for the Study of the Liver 2020.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7U7
C1K
K9.
NAPCQ
7X8
DOI 10.1007/s12072-020-10097-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Toxicology Abstracts
Environmental Sciences and Pollution Management
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1936-0541
EndPage 996
ExternalDocumentID 33128206
10_1007_s12072_020_10097_z
Genre Randomized Controlled Trial
Multicenter Study
Journal Article
GrantInformation_xml – fundername: China National Science and Technology major projects 12th 5-year plan
  grantid: 2012ZX10005004
GroupedDBID ---
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
1N0
203
29I
29~
2J2
2JN
2KG
2KM
2LR
2VQ
2~H
30V
3V.
4.4
406
408
40D
53G
5GY
5VS
67Z
6NX
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACCUX
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSNA
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
AOIJS
ARMRJ
AXYYD
B-.
BAWUL
BDATZ
BENPR
BGNMA
BKEYQ
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DIK
DNIVK
DPUIP
DU5
E3Z
EBLON
EBS
EIOEI
EJD
EN4
ESBYG
EX3
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GX1
H13
HF~
HG6
HMCUK
HMJXF
HRMNR
HYE
HZ~
IJ-
IKXTQ
IMOTQ
IWAJR
IXD
IZQ
J-C
J0Z
JBSCW
JZLTJ
KOV
LLZTM
M1P
M4Y
MA-
NAPCQ
NPVJJ
NQJWS
NU0
O9-
O93
O9I
O9J
OK1
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
QOR
QOS
R89
R9I
ROL
RPM
RPX
RSV
S16
S1Z
S27
S37
S3B
SAP
SDH
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZ9
SZN
T13
TR2
TSG
TSK
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
WOW
YLTOR
Z45
Z7U
Z87
ZMTXR
ZOVNA
~A9
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7U7
C1K
K9.
7X8
ID FETCH-LOGICAL-c375t-3851f6b3fd68800e16c65bc365518b4b8b188884016ac8240f849a75f36e04123
IEDL.DBID U2A
ISSN 1936-0533
1936-0541
IngestDate Mon Jul 21 09:36:50 EDT 2025
Fri Jul 25 21:21:28 EDT 2025
Mon Jul 21 05:46:53 EDT 2025
Tue Jul 01 00:55:07 EDT 2025
Thu Apr 24 23:12:17 EDT 2025
Fri Feb 21 02:34:42 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Traditional Chinese medicine
Tiao-gan-yi-pi granule
Chronic hepatitis B
Tiao-gan-jian-pi-jie-du granule
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-3851f6b3fd68800e16c65bc365518b4b8b188884016ac8240f849a75f36e04123
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-0924-5835
PMID 33128206
PQID 2477264687
PQPubID 1486344
PageCount 12
ParticipantIDs proquest_miscellaneous_2456430628
proquest_journals_2477264687
pubmed_primary_33128206
crossref_primary_10_1007_s12072_020_10097_z
crossref_citationtrail_10_1007_s12072_020_10097_z
springer_journals_10_1007_s12072_020_10097_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-12-01
PublicationDateYYYYMMDD 2020-12-01
PublicationDate_xml – month: 12
  year: 2020
  text: 2020-12-01
  day: 01
PublicationDecade 2020
PublicationPlace New Delhi
PublicationPlace_xml – name: New Delhi
– name: United States
– name: Tokyo
PublicationTitle Hepatology international
PublicationTitleAbbrev Hepatol Int
PublicationTitleAlternate Hepatol Int
PublicationYear 2020
Publisher Springer India
Springer Nature B.V
Publisher_xml – name: Springer India
– name: Springer Nature B.V
References Yun-Fan (CR41) 2003; 18
Lok (CR25) 2017; 67
Yong-An (CR14) 2018; 24
Arends (CR31) 2017; 6
Ri-Cheng (CR42) 2009; 39
(CR15) 2011; 3
Min (CR37) 2013; 2013
Zoutendijk (CR17) 2011; 54
Wang (CR20) 2016; 65
Jinlin (CR24) 2017; 5
Huang (CR10) 2017; 323
CR13
Aparna (CR1) 2015; 386
Liu (CR7) 2016; 64
Shi-Ming (CR6) 2007; 46
Liao (CR22) 2019; 24
Xu (CR9) 2010; 16
Yokosuka (CR18) 2010; 52
Carolina (CR33) 2012; 143
Suna, Nizar, Lok (CR28) 2014; 12
Tung-Hung, Chun-Jen (CR29) 2017; 11
Gish (CR26) 2007; 133
Shire (CR35) 2017; 6
Li (CR38) 2020; 26
Kondeva-Burdina (CR40) 2018; 111
Xiaofeng (CR3) 2009; 200
Jeng, Chen, Liaw (CR43) 2018; 25
Hua (CR36) 2018; 108
Yuen (CR16) 2011; 106
Terrault (CR23) 2016; 63
Rehermann (CR34) 1996; 97
Sarin (CR5) 2016; 10
(CR21) 2017; 67
Carolina (CR32) 2003; 39
Xing (CR39) 2017; 138
Liaw (CR8) 2009; 351
Liang (CR4) 2009; 27
Ning (CR30) 2014; 61
Ott (CR2) 2012; 30
Yao (CR19) 2010; 17
Kemal (CR27) 2014; 53
Cao (CR11) 2014; 6
Jeung-Bae (CR12) 2014; 151
D Liu (10097_CR7) 2016; 64
K Cao (10097_CR11) 2014; 6
XK Li (10097_CR38) 2020; 26
Q Ning (10097_CR30) 2014; 61
L Min (10097_CR37) 2013; 2013
H Huang (10097_CR10) 2017; 323
H Jinlin (10097_CR24) 2017; 5
H Liao (10097_CR22) 2019; 24
European Association for the Study of the Liver (10097_CR21) 2017; 67
Disease, C.S.o.H.a.C.S.o.I (10097_CR15) 2011; 3
K Jeung-Bae (10097_CR12) 2014; 151
O Yokosuka (10097_CR18) 2010; 52
J Wang (10097_CR20) 2016; 65
GR Gish (10097_CR26) 2007; 133
X Liang (10097_CR4) 2009; 27
Y-F Liaw (10097_CR8) 2009; 351
NJ Shire (10097_CR35) 2017; 6
KS Sarin (10097_CR5) 2016; 10
B Carolina (10097_CR32) 2003; 39
10097_CR13
B Rehermann (10097_CR34) 1996; 97
J Xing (10097_CR39) 2017; 138
NA Terrault (10097_CR23) 2016; 63
Y Hua (10097_CR36) 2018; 108
M Kondeva-Burdina (10097_CR40) 2018; 111
GB Yao (10097_CR19) 2010; 17
JE Arends (10097_CR31) 2017; 6
R Zoutendijk (10097_CR17) 2011; 54
M Ri-Cheng (10097_CR42) 2009; 39
AS Lok (10097_CR25) 2017; 67
S Tung-Hung (10097_CR29) 2017; 11
L Shi-Ming (10097_CR6) 2007; 46
CM Kemal (10097_CR27) 2014; 53
Y Yong-An (10097_CR14) 2018; 24
L Yun-Fan (10097_CR41) 2003; 18
S Aparna (10097_CR1) 2015; 386
B Carolina (10097_CR33) 2012; 143
MF Yuen (10097_CR16) 2011; 106
WJ Jeng (10097_CR43) 2018; 25
Y Suna (10097_CR28) 2014; 12
WS Xu (10097_CR9) 2010; 16
JJ Ott (10097_CR2) 2012; 30
L Xiaofeng (10097_CR3) 2009; 200
References_xml – volume: 5
  start-page: 297
  issue: 4
  year: 2017
  end-page: 318
  ident: CR24
  article-title: Guideline of prevention and treatment for chronic hepatitis B (2015 Update)
  publication-title: J Clin Transl Hepatol
  doi: 10.14218/JCTH.2016.00019
– volume: 323
  start-page: 36
  year: 2017
  end-page: 43
  ident: CR10
  article-title: Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2017.03.016
– volume: 106
  start-page: 1264
  issue: 7
  year: 2011
  end-page: 1271
  ident: CR16
  article-title: Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.45
– volume: 26
  start-page: 330
  issue: 5
  year: 2020
  end-page: 338
  ident: CR38
  article-title: Adefovir dipivoxil plus chinese medicine in HBeAg-positive chronic hepatitis B patients: a randomized controlled 48-week trial
  publication-title: Chin J Integr Med
  doi: 10.1007/s11655-020-3250-0
– volume: 143
  start-page: 963
  issue: 4
  year: 2012
  end-page: 973.e9
  ident: CR33
  article-title: Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2012.07.014
– volume: 30
  start-page: 2212
  issue: 12
  year: 2012
  end-page: 2219
  ident: CR2
  article-title: Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2011.12.116
– volume: 2013
  start-page: 1
  year: 2013
  end-page: 12
  ident: CR37
  article-title: Modeling and simulating dynamics of complete- and poor-response chronic hepatitis b chinese patients for adefovir and traditional chinese medicine plus adefovir therapy
  publication-title: Evid-Based Complement Altern Med
  doi: 10.1155/2013/767290
– volume: 6
  start-page: 461
  issue: 4
  year: 2017
  end-page: 476
  ident: CR31
  article-title: New viral and immunological targets for hepatitis B treatment and cure: a review
  publication-title: Infect Dis Therapy.
  doi: 10.1007/s40121-017-0173-y
– volume: 24
  start-page: 653
  issue: 9
  year: 2018
  end-page: 660
  ident: CR14
  article-title: Chinese herbal medicine combined with entecavir for HBeAg positive chronic hepatitis B: study protocol for a multi-center, double-blind randomized-controlled trial
  publication-title: Chin J Integr Med
  doi: 10.1007/s11655-018-3011-5
– volume: 151
  start-page: 279
  issue: 1
  year: 2014
  end-page: 286
  ident: CR12
  article-title: A traditional herbal formula, Hyangsa-Pyeongwi san (HPS), improves quality of life (QoL) of the patient with functional dyspepsia (FD): randomized double-blinded controlled trial
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2013.10.033
– volume: 52
  start-page: 791
  issue: 6
  year: 2010
  end-page: 799
  ident: CR18
  article-title: Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2009.12.036
– volume: 63
  start-page: 261
  issue: 1
  year: 2016
  ident: CR23
  article-title: AASLD guidelines for treatment of chronic hepatitis B
  publication-title: Hepatology (Baltimore, MD)
  doi: 10.1002/hep.28156
– volume: 67
  start-page: 847
  issue: 4
  year: 2017
  end-page: 861
  ident: CR25
  article-title: Hepatitis B cure: from discovery to regulatory approval
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.05.008
– volume: 27
  start-page: 6550
  issue: 47
  year: 2009
  end-page: 6557
  ident: CR4
  article-title: Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.08.048
– volume: 67
  start-page: 370
  issue: 2
  year: 2017
  end-page: 398
  ident: CR21
  article-title: Electronic address, e.e.e. and L. European Association for the Study of the, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
  publication-title: J Hepatol.
  doi: 10.1016/j.jhep.2017.03.021
– volume: 53
  start-page: 31
  issue: 1
  year: 2014
  end-page: 36
  ident: CR27
  article-title: Four-year study of entecavir efficacy and safety in nucleos(t)ide-naïve HBeAg positive chronic hepatitis B patients
  publication-title: Acta Clinica Croatica
– volume: 39
  start-page: 595
  issue: 4
  year: 2003
  end-page: 605
  ident: CR32
  article-title: Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(03)00292-7
– volume: 24
  start-page: 105
  issue: 2
  year: 2019
  end-page: 115
  ident: CR22
  article-title: Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy
  publication-title: Antivir Ther
  doi: 10.3851/IMP3280
– volume: 6
  start-page: 259
  issue: 3
  year: 2014
  end-page: 267
  ident: CR11
  article-title: Efficacy of Zhengtian Pill for migraine prophylaxis: A randomized, multicenter, double-blind, placebo-controlled, parallel-group study
  publication-title: Eur J Integr Med
  doi: 10.1016/j.eujim.2014.01.005
– volume: 64
  start-page: 390
  issue: 2
  year: 2016
  end-page: 404
  ident: CR7
  article-title: Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity
  publication-title: Hepatology
  doi: 10.1002/hep.28594
– volume: 46
  start-page: 45
  issue: 1
  year: 2007
  end-page: 52
  ident: CR6
  article-title: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.08.021
– volume: 138
  start-page: 215
  year: 2017
  end-page: 222
  ident: CR39
  article-title: Integrative hepatoprotective efficacy comparison of raw and vinegar-baked Radix Bupleuri using nuclear magnetic resonance-based metabolomics
  publication-title: J Pharm Biomed Anal
  doi: 10.1016/j.jpba.2017.02.015
– volume: 97
  start-page: 1655
  issue: 7
  year: 1996
  end-page: 1665
  ident: CR34
  article-title: Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection
  publication-title: J Clin Invest.
  doi: 10.1172/JCI118592
– volume: 108
  start-page: 744
  year: 2018
  end-page: 752
  ident: CR36
  article-title: Hepatoprotective and inhibiting HBV effects of polysaccharides from roots of
  publication-title: Int J Biol Macromol
  doi: 10.1016/j.ijbiomac.2017.10.171
– volume: 18
  start-page: 246
  issue: 3
  year: 2003
  end-page: 252
  ident: CR41
  article-title: Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy
  publication-title: J Gastroenterol Hepatol
  doi: 10.1046/j.1440-1746.2003.02976.x
– volume: 39
  start-page: 14
  issue: 1
  year: 2009
  end-page: 20
  ident: CR42
  article-title: Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy
  publication-title: Hepatol Res
  doi: 10.1111/j.1872-034X.2008.00411.x
– volume: 25
  start-page: 421
  issue: 4
  year: 2018
  end-page: 428
  ident: CR43
  article-title: Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy
  publication-title: J Viral Hepat
  doi: 10.1111/jvh.12833
– volume: 3
  start-page: 13
  year: 2011
  end-page: 24
  ident: CR15
  article-title: Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version)
  publication-title: Chin J Hepatol (Chin).
– ident: CR13
– volume: 12
  start-page: 16
  issue: 1
  year: 2014
  end-page: 26
  ident: CR28
  article-title: Management of hepatitis B: our practice and how it relates to the guidelines
  publication-title: Clin Gastroenterol Hepatol.
  doi: 10.1016/j.cgh.2013.04.036
– volume: 111
  start-page: 631
  year: 2018
  end-page: 640
  ident: CR40
  article-title: In vitro/in vivo antioxidant and hepatoprotective potential of defatted extract and flavonoids isolated from Boiss. (Fabaceae)
  publication-title: Food Chem Toxicol
  doi: 10.1016/j.fct.2017.12.020
– volume: 6
  start-page: 186
  issue: 2
  year: 2017
  end-page: 194
  ident: CR35
  article-title: Cure strategies for hepatitis B virus: the promise of immunotherapy
  publication-title: Clin Pharmacol Drug Dev.
  doi: 10.1002/cpdd.317
– volume: 351
  start-page: 1521
  issue: 15
  year: 2009
  end-page: 1531
  ident: CR8
  article-title: Lamivudine for patients with chronic hepatitis B and advanced liver disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa033364
– volume: 16
  start-page: 2028
  issue: 16
  year: 2010
  end-page: 2037
  ident: CR9
  article-title: Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v16.i16.2028
– volume: 65
  start-page: 700
  issue: 4
  year: 2016
  end-page: 710
  ident: CR20
  article-title: Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2016.05.029
– volume: 17
  start-page: 51
  year: 2010
  end-page: 58
  ident: CR19
  article-title: Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients
  publication-title: J Viral Hepatitis
  doi: 10.1111/j.1365-2893.2010.01271.x
– volume: 386
  start-page: 1546
  issue: 10003
  year: 2015
  end-page: 1555
  ident: CR1
  article-title: Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(15)61412-X
– volume: 61
  start-page: 777
  issue: 4
  year: 2014
  end-page: 784
  ident: CR30
  article-title: Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2014.05.044
– volume: 54
  start-page: 443
  issue: 2
  year: 2011
  end-page: 451
  ident: CR17
  article-title: Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response
  publication-title: Hepatology
  doi: 10.1002/hep.24406
– volume: 200
  start-page: 39
  issue: 1
  year: 2009
  end-page: 47
  ident: CR3
  article-title: Evaluation of the impact of hepatitis B vaccination among children born during 1992–2005 in China
  publication-title: J Infect Dis
  doi: 10.1086/599332
– volume: 10
  start-page: 1
  issue: 1
  year: 2016
  end-page: 98
  ident: CR5
  article-title: Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
  publication-title: Hepatol Int
  doi: 10.1007/s12072-015-9675-4
– volume: 11
  start-page: 590
  issue: 5
  year: 2017
  end-page: 603
  ident: CR29
  article-title: Combination therapy for chronic hepatitis B: current updates and perspectives
  publication-title: Gut Liver
  doi: 10.5009/gnl16215
– volume: 133
  start-page: 1437
  issue: 5
  year: 2007
  end-page: 1444
  ident: CR26
  article-title: Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2007.08.025
– volume: 65
  start-page: 700
  issue: 4
  year: 2016
  ident: 10097_CR20
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2016.05.029
– volume: 10
  start-page: 1
  issue: 1
  year: 2016
  ident: 10097_CR5
  publication-title: Hepatol Int
  doi: 10.1007/s12072-015-9675-4
– volume: 46
  start-page: 45
  issue: 1
  year: 2007
  ident: 10097_CR6
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2006.08.021
– volume: 386
  start-page: 1546
  issue: 10003
  year: 2015
  ident: 10097_CR1
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(15)61412-X
– volume: 151
  start-page: 279
  issue: 1
  year: 2014
  ident: 10097_CR12
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2013.10.033
– volume: 17
  start-page: 51
  year: 2010
  ident: 10097_CR19
  publication-title: J Viral Hepatitis
  doi: 10.1111/j.1365-2893.2010.01271.x
– volume: 108
  start-page: 744
  year: 2018
  ident: 10097_CR36
  publication-title: Int J Biol Macromol
  doi: 10.1016/j.ijbiomac.2017.10.171
– volume: 138
  start-page: 215
  year: 2017
  ident: 10097_CR39
  publication-title: J Pharm Biomed Anal
  doi: 10.1016/j.jpba.2017.02.015
– volume: 24
  start-page: 653
  issue: 9
  year: 2018
  ident: 10097_CR14
  publication-title: Chin J Integr Med
  doi: 10.1007/s11655-018-3011-5
– volume: 54
  start-page: 443
  issue: 2
  year: 2011
  ident: 10097_CR17
  publication-title: Hepatology
  doi: 10.1002/hep.24406
– volume: 52
  start-page: 791
  issue: 6
  year: 2010
  ident: 10097_CR18
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2009.12.036
– volume: 11
  start-page: 590
  issue: 5
  year: 2017
  ident: 10097_CR29
  publication-title: Gut Liver
  doi: 10.5009/gnl16215
– volume: 25
  start-page: 421
  issue: 4
  year: 2018
  ident: 10097_CR43
  publication-title: J Viral Hepat
  doi: 10.1111/jvh.12833
– volume: 67
  start-page: 847
  issue: 4
  year: 2017
  ident: 10097_CR25
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.05.008
– volume: 63
  start-page: 261
  issue: 1
  year: 2016
  ident: 10097_CR23
  publication-title: Hepatology (Baltimore, MD)
  doi: 10.1002/hep.28156
– volume: 351
  start-page: 1521
  issue: 15
  year: 2009
  ident: 10097_CR8
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa033364
– volume: 6
  start-page: 259
  issue: 3
  year: 2014
  ident: 10097_CR11
  publication-title: Eur J Integr Med
  doi: 10.1016/j.eujim.2014.01.005
– volume: 12
  start-page: 16
  issue: 1
  year: 2014
  ident: 10097_CR28
  publication-title: Clin Gastroenterol Hepatol.
  doi: 10.1016/j.cgh.2013.04.036
– volume: 6
  start-page: 461
  issue: 4
  year: 2017
  ident: 10097_CR31
  publication-title: Infect Dis Therapy.
  doi: 10.1007/s40121-017-0173-y
– volume: 323
  start-page: 36
  year: 2017
  ident: 10097_CR10
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1016/j.taap.2017.03.016
– volume: 5
  start-page: 297
  issue: 4
  year: 2017
  ident: 10097_CR24
  publication-title: J Clin Transl Hepatol
  doi: 10.14218/JCTH.2016.00019
– volume: 61
  start-page: 777
  issue: 4
  year: 2014
  ident: 10097_CR30
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2014.05.044
– volume: 26
  start-page: 330
  issue: 5
  year: 2020
  ident: 10097_CR38
  publication-title: Chin J Integr Med
  doi: 10.1007/s11655-020-3250-0
– volume: 64
  start-page: 390
  issue: 2
  year: 2016
  ident: 10097_CR7
  publication-title: Hepatology
  doi: 10.1002/hep.28594
– volume: 53
  start-page: 31
  issue: 1
  year: 2014
  ident: 10097_CR27
  publication-title: Acta Clinica Croatica
– volume: 133
  start-page: 1437
  issue: 5
  year: 2007
  ident: 10097_CR26
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2007.08.025
– volume: 106
  start-page: 1264
  issue: 7
  year: 2011
  ident: 10097_CR16
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2011.45
– volume: 67
  start-page: 370
  issue: 2
  year: 2017
  ident: 10097_CR21
  publication-title: J Hepatol.
  doi: 10.1016/j.jhep.2017.03.021
– volume: 39
  start-page: 14
  issue: 1
  year: 2009
  ident: 10097_CR42
  publication-title: Hepatol Res
  doi: 10.1111/j.1872-034X.2008.00411.x
– volume: 39
  start-page: 595
  issue: 4
  year: 2003
  ident: 10097_CR32
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(03)00292-7
– volume: 27
  start-page: 6550
  issue: 47
  year: 2009
  ident: 10097_CR4
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.08.048
– volume: 143
  start-page: 963
  issue: 4
  year: 2012
  ident: 10097_CR33
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2012.07.014
– volume: 6
  start-page: 186
  issue: 2
  year: 2017
  ident: 10097_CR35
  publication-title: Clin Pharmacol Drug Dev.
  doi: 10.1002/cpdd.317
– volume: 200
  start-page: 39
  issue: 1
  year: 2009
  ident: 10097_CR3
  publication-title: J Infect Dis
  doi: 10.1086/599332
– volume: 16
  start-page: 2028
  issue: 16
  year: 2010
  ident: 10097_CR9
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v16.i16.2028
– volume: 24
  start-page: 105
  issue: 2
  year: 2019
  ident: 10097_CR22
  publication-title: Antivir Ther
  doi: 10.3851/IMP3280
– volume: 97
  start-page: 1655
  issue: 7
  year: 1996
  ident: 10097_CR34
  publication-title: J Clin Invest.
  doi: 10.1172/JCI118592
– ident: 10097_CR13
– volume: 3
  start-page: 13
  year: 2011
  ident: 10097_CR15
  publication-title: Chin J Hepatol (Chin).
– volume: 2013
  start-page: 1
  year: 2013
  ident: 10097_CR37
  publication-title: Evid-Based Complement Altern Med
  doi: 10.1155/2013/767290
– volume: 18
  start-page: 246
  issue: 3
  year: 2003
  ident: 10097_CR41
  publication-title: J Gastroenterol Hepatol
  doi: 10.1046/j.1440-1746.2003.02976.x
– volume: 111
  start-page: 631
  year: 2018
  ident: 10097_CR40
  publication-title: Food Chem Toxicol
  doi: 10.1016/j.fct.2017.12.020
– volume: 30
  start-page: 2212
  issue: 12
  year: 2012
  ident: 10097_CR2
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2011.12.116
SSID ssj0055616
Score 2.2856424
Snippet Background and aim Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind,...
Traditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind, placebo-controlled,...
Background and aimTraditional Chinese medicine (TCM) is widely accepted and prescribed in China alongside Nucleoside analogs (NAs). In this double-blind,...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 985
SubjectTerms Adverse events
Antigens
Antiviral Agents - therapeutic use
Antiviral drugs
Clinical trials
Colorectal Surgery
Deoxyribonucleic acid
DNA
DNA, Viral
Drug Combinations
Drugs, Chinese Herbal - therapeutic use
Enzymes
Granular materials
Guanine - analogs & derivatives
Guanine - therapeutic use
Hepatitis
Hepatitis B
Hepatitis B e antigen
Hepatitis B e Antigens
Hepatitis B surface antigen
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Hepatology
Herbal medicine
Humans
Liver
Medicine
Medicine & Public Health
Nucleoside analogs
Original Article
Placebos
Statistical analysis
Surgery
Therapy
Traditional Chinese medicine
Treatment Outcome
Title Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial
URI https://link.springer.com/article/10.1007/s12072-020-10097-z
https://www.ncbi.nlm.nih.gov/pubmed/33128206
https://www.proquest.com/docview/2477264687
https://www.proquest.com/docview/2456430628
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED_WFkZfytZ1nbcsqLC3xWBblizvLS1tQkf71ED6ZCxZHoEsKXGSh-yf350tJ4x0hT77JH_8JN2df_cB8M1ERsah1X4gA0t_q0rcUhRMUyiRRFxSjW-KtriXw1F8OxZjlxRWtdHuLSVZn9S7ZLcoSCKf3J2Qsg_8zQEcCfLdcRWPon57_lK_R9lwyegrozXjUmWen-NfdbRnY-7xo7XauXkHJ85eZP0G4Pfwxs5O4e2dY8Q_wB9i9U2-niwYvoau2z0waoptK8sQD42DW_6coYHKhpe2_8tvYrXWlpmmOC6KUmj1clKxS-ZqrVY_WM5QlRXz35ONLXrMhbVPbcHqZh9nMLq5frga-q6hgm94IpY-R_OqlJqXhcRtG9hQGim04ZLKsulYKx2iQ4wuXyhzo1DXlypO80SUXFqqy8U_wuFsPrOfgCU2NUWqTZIaHcc6SHWuiDJUQhUqNMKDsP2umXHVxqnpxTTb1UkmLDLEIquxyDYefN-OeWpqbbwo3Wnhyty-q7IoRm9BxlIlHlxsL-OOIRokn9n5imQEmmGUO-rBeQPz9naco76OAulBr8V9N_n_n-Xz68S_wHFUr0GKiunA4XKxsl_RtlnqLhz1B48_r7twMBiH3Xph_wU8nPAT
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT8MwDLZ4SMAF8aY8g8QNKrVNm6bcNgQaMDgxiVvVpCmaBBuig8P489htugnxkDjXSR9fEtv1ZxvgWAdahL5Rric8Q3-rCtxSRKbJZRQHXFCNb2Jb3IlOL7x-iB5sUljZsN2bkGR1Uk-T3QIvDlxyd3zKPnDHszCPxoAkIlcvaDXnL_V7FHUsGX1ltGZsqszPc3xVR99szG_x0UrtXK7AsrUXWasGeBVmzGANFm5tRHwdPiiqr7P3_ivD11BVuwdGTbFNaRjioXBwEz9naKCyTtu0Ht2aq_VumK6L46IoUatH_ZK1ma21Wp6xjKEqy4fP_bHJT5mltT-ZnFXNPjagd3lxf95xbUMFV_M4GrkczatCKF7kAretZ3yhRaQ0F1SWTYVKKh8dYnT5fJFpibq-kGGSxVHBhaG6XHwT5gbDgdkGFptE54nScaJVGCovUZmkkKGMZC59HTngN9811bbaODW9eEqndZIJixSxSCss0rEDJ5MxL3WtjT-l9xq4UrvvyjQI0VsQoZCxA0eTy7hjKAySDczwjWQiNMMod9SBrRrmye04R30deMKB0wb36eS_P8vO_8QPYbFzf9tNu1d3N7uwFFTrkRgyezA3en0z-2jnjNRBtaw_AYm38IE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3JTsQwDLVYJMQFsVPWIHGDirZp05TbsIyGVRwYiVvVpCkaCTqIKRyGn8fuMgNikTjXSZeXxHZtPwPsaU8L3zXKdoRj6G9VhluKkmlSGYQeF8TxTdkWN6LT9S_ug_tPVfxltnsTkqxqGoilKS8On9PscFz45jmhZ5Pr41Ilgj2chGk8jl1a112v1ZzF1PtRVHFl9JvRsqnLZn6e46tq-mZvfouVliqoPQ9zte3IWhXYCzBh8kWYua6j40vwThF-nbz1Xhi-kipbPzBqkG0GhiE2Cgc3sXSGxirrHJvWg13lbb0ZpiuiXBSlNOuiN2DHrOZdHRyxhKFaS_tPvaFJD1id4v5oUlY2_liGbvvs7qRj180VbM3DoLA5mlqZUDxLBW5hx7hCi0BpLoiiTflKKhedY3T_XJFoiXo_k36UhEHGhSGOLr4CU3k_N2vAQhPpNFI6jLTyfeVEKpEUPpSBTKWrAwvc5rvGumYepwYYj_GYM5mwiBGLuMQiHlqwPxrzXPFu_Cm92cAV13twEHs-eg7CFzK0YHd0GXcPhUSS3PRfSSZAk4zqSC1YrWAe3Y5z1N2eIyw4aHAfT_77s6z_T3wHZm5P2_HV-c3lBsx65XKkZJlNmCpeXs0WmjyF2i5X9Qd2i_S9
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Entecavir+combining+Chinese+herbal+medicine+for+HBeAg-positive+chronic+hepatitis+B+patients%3A+a+randomized%2C+controlled+trial&rft.jtitle=Hepatology+international&rft.au=Li%2C+Xiaoke&rft.au=Zhou%2C+Daqiao&rft.au=Chi%2C+Xiaoling&rft.au=Li%2C+Qin&rft.date=2020-12-01&rft.eissn=1936-0541&rft.volume=14&rft.issue=6&rft.spage=985&rft_id=info:doi/10.1007%2Fs12072-020-10097-z&rft_id=info%3Apmid%2F33128206&rft.externalDocID=33128206
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1936-0533&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1936-0533&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1936-0533&client=summon